ストックスクリーナーアプリを入手
18.71
0.97%
0.19
前日終値:
$18.52
開ける：
$18.37
24時間の取引高:
1.09M
Relative Volume:
0.37
時価総額：
$59.73B
収益：
$29.91B
当期純損益:
$1.30B
株価収益率:
46.13
EPS:
0.4056
ネットキャッシュフロー:
$3.49B
1週間 パフォーマンス:
+4.70%
1か月 パフォーマンス:
+2.69%
6か月 パフォーマンス:
+1.30%
1年 パフォーマンス:
+32.81%
1日の値動き範囲:
$18.37
$18.75
1週間の範囲:
$17.75
$18.75
52週間の値動き範囲:
$12.99
$19.10
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Compare TAK vs TEVA, HLN, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
18.70 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.74 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.285 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
74.33 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
548.71 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-08 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2026-01-13 | 再開されました | Morgan Stanley | Overweight |
| 2025-04-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-07-19 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-10-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-01 | 開始されました | Cowen | Market Perform |
| 2019-08-15 | ダウングレード | Daiwa Securities | Outperform → Neutral |
すべてを表示
Takeda Pharmaceutical Co Adr (TAK) 最新ニュース
TKDA Stock Price and Chart — HAN:TKDA - TradingView
TKDA Forecast — Price Target — Prediction for 2027 - TradingView
Book value per share of Takeda Pharmaceutical Co. Ltd. Sponsored ADR – HAN:TKDA - TradingView
ETFs Investing in Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stocks - TradingView
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD - Zacks Investment Research
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - GlobeNewswire Inc.
Teva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and history - Yahoo Finance UK
Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history - Yahoo Finance Singapore
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Dr Reddy's Laboratories stock gains attention on QDENGA vaccine deal - ad-hoc-news.de
NY stocks mixed, Dow falls for first time in 3 days on rate hike concerns - finance.biggo.com
SGIOY Stock Price, Quote & News - Syfe
Organon & Co. (OGN) Peer Comparison – Compare with Others - Value Research
Teva Pharma Industries Ltd ADR (TEVA) Peer Comparison – Compare with Others - Value Research
Protagonist Therapeutics receives FDA approval for polycythemia vera drug By Investing.com - Investing.com India
Protagonist Therapeutics receives FDA approval for polycythemia vera drug - Investing.com
Analysts Offer Insights on Healthcare Companies: Sysmex (OtherSSMXF) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Takeda Pharmaceutical Co Ltd (ADR) (TAK) News, Articles, Events & Latest Updates - Stocktwits
Takeda (NYSE:TAK) Climbs Into Focus On Sleep Disorder Milestone - Kalkine Media
Takeda (TAK) Q1 2026 Earnings Call Transcript - theglobeandmail.com
US FDA approves Takeda’s sleep disorder pill By Reuters - Investing.com
Takeda Pharmaceutical (TAK) Slips 0.93% to $17.09 as Defensive Sector Shows Mixed ToneDealer Positioning - dars.gov.et
Corporate Lobbying Dashboard - Quiver Quantitative
Murata ADR Surges 15%, SoftBank Group Jumps 7% as Semiconductor, Tech Stocks See Short-Covering - finance.biggo.com
Takeda Pharmaceutical (TAK) Gains 2.5%; Approaches Key Resistance LevelStrangle Setup - dars.gov.et
TAK: Takeda Pharmaceutical Co Ltd (ADR) Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Takeda invests $30M to build Indonesian plasma ecosystem - grafa.com
Form 144 Takeda Pharmaceutical Company Limited For: 13 July By Investing.com - Investing.com Canada
6 High-Yield International Dividend Stocks Analysts Love - Forbes
TAKTakeda Pharmaceutical Co ADR Latest SEC Filings - Finviz
India Celiac Disease Treatment Market Size & Outlook, 2033 - grandviewresearch.com
0A87 Forecast — Price Target — Prediction for 2027 - TradingView
TAK-755 from Takeda Pharmaceutical Co.enzyme replacement for a rare bleeding disorder - Ad-hoc-news.de
Takeda Pharmaceutical Co. Ltd. Sponsored ADR Actuals & Estimates (LS:A1CWZF) - TradingView
A1CWZF Forecast — Price Target — Prediction for 2027 - TradingView
Takeda Pharmaceutical Co Adr (TAK) 財務データ
収益
当期純利益
現金流量
EPS
5.91%
大文字化:
|
ボリューム (24 時間):